How Enteric Microbiome Mitochondrial Function

Print Friendly, PDF & Email

Richard Frye, MD, PhD, FAAP, FAAN, CPI, discusses how  Enteric (gut) Microbiome Modulates Mitochondrial Function.

Talking points include:

  • The enteric (gut) microbiome has an important influence on health and disease states in humans.
  • The enteric  microbiome influences the human host using chemical mediators, some of which can directly affect mitochondrial function
  • Short chain fatty acids produced by gut bacteria not only modulate mitochondrial function and cellular regulatory pathways, but can also be used as mitochondrial fuels.

About The Speaker

Dr. Richard Frye is the Director of Autism Research at Arkansas Children’s Hospital Research Institute, Director of the Autism Multispecialty Clinic, and Co-Director of the Neurometabolic Clinic at Arkansas Children’s Hospital and Associate Professor in Pediatrics at the University of Arkansas for Medical Sciences. He received his MD/PhD from Georgetown University in 1998. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology, and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He holds board certifications in Pediatrics, and in Neurology with Special Competence in Child Neurology. Dr. Frye is a national leader in autism research. He has authored over 100 peer-reviewed publications and book chapters, and serves on several editorial boards of prestigious scientific and medical journals.

Over the past several years he has completed several clinical studies on children with autism spectrum disorder (ASD), including studies focusing on defining the clinical, behavioral, cognitive, genetic, and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that address underlying physiological abnormalities in children with ASD, including open-labels on tetrahydrobiopterin, cobalamin and folinic acid and a recent double-blind placebo controlled trial on folinic acid. Future research efforts are focused on defining physiological endophenotypes of children with ASD and developing targeted treatments.

Date: 09/22/2017
PDF: Click Here
Listen Now: Click Here
View Slides: Click Here

Related Articles